Pantoprazole Polpharma

Pantoprazole, the active ingredient in Pantoprazole Polpharma, is a proton pump inhibitor presented as a strength/form for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and Zollinger‑Ellison syndrome in adults. GNH USA supplies Pantoprazole Polpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Pantoprazole Polpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole is a proton pump inhibitor that acts on the gastric acid secretion pathway.

- Gastro‑oesophageal reflux disease (GERD): Provides relief of heartburn and promotes healing of erosive esophagitis. - Erosive gastritis and duodenal ulcer: Facilitates ulcer healing and reduces recurrence. - Zollinger‑Ellison syndrome: Controls excessive gastric acid secretion associated with gastrin‑producing tumors. - Prevention of NSAID‑induced gastric ulcers: Lowers the risk of ulcer development in patients requiring long‑term NSAID therapy.

Pantoprazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: Mild to moderate headache reported in clinical use. - Diarrhea: Loose stools occurring during treatment. - Abdominal pain: Discomfort or cramping in the stomach area. - Nausea: Feeling of queasiness without vomiting. - Flatulence: Increased intestinal gas. - Constipation: Reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: Severe colitis associated with antibiotic‑related flora changes. - Acute interstitial nephritis: Inflammation of kidney interstitium that may impair renal function. - Hypomagnesemia: Low serum magnesium levels with prolonged use. - Stevens‑Johnson syndrome: Rare severe skin reaction. - Hepatic injury: Elevated liver enzymes or hepatitis. - Fracture risk: Potential increase in bone fracture incidence with long‑term therapy.

When prescribing Pantoprazole, clinicians should consider several safety aspects.

- Assess renal function: Adjust use in patients with severe renal impairment. - Monitor electrolytes: Check magnesium levels during prolonged therapy. - Evaluate bone health: Use caution in patients at risk for osteoporosis. - Review concomitant medications: Consider potential interactions with drugs that require acidic pH for absorption. - Pregnancy and lactation: Use only if clearly needed; weigh benefits against potential risks. - Store at ambient temperature: Keep below 25°C, in the original packaging, protected from moisture.

Pantoprazole can interact with several medicines, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Ketoconazole: Reduced absorption of ketoconazole when gastric pH is increased. - Atazanavir: Decreased plasma concentrations of atazanavir, compromising antiviral efficacy. - Clopidogrel: Potential reduction of clopidogrel’s antiplatelet effect.

Moderate 

---

---  

---  

---  

---  

---  

---  t 

--- 

--- 

--- 

--- 

--- 

--- 

--- 

---